David Amsellem

Piper Sandler | Healthcare

David Amsellem is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #2377 out of 4613 analysts, they have issued 36 stock ratings with a success rate of 64.32% and an average return of 13.10%.

David Amsellem has a well-established track record, with 36 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 64.32% and an average return of 13.10%, underscoring their expertise and ability to identify winning opportunities for investors.

#2377

Out of 4613

36

Total Ratings

+64.32%

Success Rate

+13.10%

Average Return

Recent Ratings Analysis

BIIB

Apr 14, 2026

Target

$214.00

Current

$178.96

Performance

0.00%

David Amsellem rated BIIB as Overweight on Apr 14, 2026, setting a price target of 214. Shares have remained stable near 178.96, leaving the 214 target still in play.

DFTX

Apr 10, 2026

Target

$49.00

Current

$21.93

Performance

1.86%

On Apr 10, 2026, DFTX was given a Overweight rating by David Amsellem, with a target price of 49. The stock traded sideways with a 1.86% move, keeping the bullish thesis unresolved.

ALKS

Mar 24, 2026

Target

$43.00

Current

$33.87

Performance

19.26%

ALKS received a Overweight rating from David Amsellem on Mar 24, 2026, aiming for 43. Momentum has favored the Buy call, with shares climbing from 33.87 to 33.87, rewarding those who trusted the recommendation.

JAZZ

Mar 19, 2026

Target

$232.00

Current

$201.06

Performance

10.59%

On Mar 19, 2026, David Amsellem published a Overweight outlook on JAZZ, with a target of 232. Shares gained 10.59%, underscoring the accuracy of the bullish outlook toward 232.

TEVA

Mar 04, 2026

Target

$41.00

Current

$31.77

Performance

—

David Amsellem on Mar 04, 2026 assigned TEVA a Overweight rating, with a price target of 41. The recommendation remains pending validation as shares consolidate around 31.77.

PTHS

Feb 27, 2026

Target

$48.00

Current

$23.00

Performance

-12.75%

On Feb 27, 2026, David Amsellem reaffirmed PTHS with a Overweight rating, targeting 48. Shares slid 12.75% despite the recommendation, highlighting downside risks.

BMY

Feb 23, 2026

Target

$75.00

Current

$58.08

Performance

-5.18%

BMY was rated Overweight by David Amsellem on Feb 23, 2026, with a price objective of 75. This case shows how bullish projections can fail, with the stock now below 58.08.

AMGN

Feb 18, 2026

Target

$432.00

Current

$350.95

Performance

-7.58%

On Feb 18, 2026, David Amsellem initiated coverage on AMGN with a Overweight rating and target of 432. The Buy call has yet to be validated as shares remain 81.05 away from the target.

ABBV

Feb 18, 2026

Target

$299.00

Current

$210.32

Performance

-8.04%

David Amsellem issued a Overweight recommendation for ABBV on Feb 18, 2026, price target set at 299. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

VTRS

Jan 28, 2026

Target

$12.00

Current

$13.91

Performance

7.25%

On Jan 28, 2026, VTRS was evaluated by David Amsellem, who gave a Neutral rating and target of 12. Investors who stayed in despite the Hold saw upside of 7.25%.

AXSM

Jan 16, 2026

Target

$223.00

Current

$184.18

Performance

3.90%

David Amsellem rated AXSM as Overweight on Jan 16, 2026, setting a price target of 223. Shares have remained stable near 184.18, leaving the 223 target still in play.

FENC

Jan 09, 2026

Target

$18.00

Current

$6.25

Performance

-19.56%

On Jan 09, 2026, FENC was given a Overweight rating by David Amsellem, with a target price of 18. Despite the Buy call, shares fell from 6.25 to 6.25, challenging the optimistic stance.

ESPR

Nov 25, 2025

Target

$9.00

Current

$2.05

Performance

-44.44%

ESPR received a Overweight rating from David Amsellem on Nov 25, 2025, aiming for 9. The rating hasn’t played out as hoped, with the stock trading 44.44% below expectations.

AQST

Nov 07, 2025

Target

$8.00

Current

$4.15

Performance

-31.29%

On Nov 07, 2025, David Amsellem published a Overweight outlook on AQST, with a target of 8. Market action contradicted the Buy thesis, as shares slipped to 4.15.

XERS

Nov 07, 2025

Target

$8.00

Current

$6.07

Performance

-18.30%

David Amsellem on Nov 07, 2025 assigned XERS a Neutral rating, with a price target of 8. The call successfully avoided chasing as shares lost 18.30%.

INDV

Oct 31, 2025

Target

$41.00

Current

$32.97

Performance

12.26%

On Oct 31, 2025, David Amsellem reaffirmed INDV with a Overweight rating, targeting 41. The recommendation was supported by strong follow-through as the stock rose from 32.97 to 32.97.

AMRX

Oct 31, 2025

Target

$13.00

Current

$13.12

Performance

21.26%

AMRX was rated Overweight by David Amsellem on Oct 31, 2025, with a price objective of 13. A bullish response from the market helped close the gap of -0.12 to the target.

NBIX

Oct 29, 2025

Target

$179.00

Current

$130.81

Performance

-5.22%

On Oct 29, 2025, David Amsellem initiated coverage on NBIX with a Overweight rating and target of 179. The Buy call has yet to be validated as shares remain 48.19 away from the target.

SUPN

Oct 09, 2025

Target

$65.00

Current

$50.11

Performance

1.21%

David Amsellem issued a Overweight recommendation for SUPN on Oct 09, 2025, price target set at 65. The target of 65 remains in play, though confirmation will depend on future moves.

AMPH

Aug 08, 2025

Target

$25.00

Current

$21.38

Performance

-10.21%

On Aug 08, 2025, AMPH was evaluated by David Amsellem, who gave a Neutral rating and target of 25. The Hold call avoided chasing into subsequent weakness of 10.21%.

CORT

Aug 01, 2025

Target

$121.00

Current

$43.68

Performance

-36.70%

David Amsellem rated CORT as Overweight on Aug 01, 2025, setting a price target of 121. The stock has underperformed, dropping 36.70% despite the bullish target of 121.

SAGE

Jun 17, 2025

Target

$8.50

Current

$8.68

Performance

-4.82%

On Jun 17, 2025, SAGE was given a Neutral rating by David Amsellem, with a target price of 8.5. Market indecision, reflected in sideways trading near 8.68, supported the cautious call.

OPTN

Mar 21, 2025

Target

$9.00

Current

$9.60

Performance

4.92%

OPTN received a Neutral rating from David Amsellem on Mar 21, 2025, aiming for 9. Shares remained flat at 9.6, aligning with the neutral rating.

COLL

Feb 04, 2025

Target

$36.00

Current

$35.64

Performance

15.23%

On Feb 04, 2025, David Amsellem published a Neutral outlook on COLL, with a target of 36. The Hold call missed some of the bullish momentum as shares advanced toward 36.

ITCI

Jan 14, 2025

Target

$132.00

Current

$131.87

Performance

3.92%

David Amsellem on Jan 14, 2025 assigned ITCI a Neutral rating, with a price target of 132. The Hold stance reflected consolidation, as shares held near 131.87.

AVDL

Jan 10, 2025

Target

$13.00

Current

$21.64

Performance

173.92%

On Jan 10, 2025, David Amsellem reaffirmed AVDL with a Overweight rating, targeting 13. The recommendation was supported by strong follow-through as the stock rose from 21.64 to 21.64.

ANIP

Oct 11, 2024

Target

$68.00

Current

$78.29

Performance

37.01%

ANIP was rated Overweight by David Amsellem on Oct 11, 2024, with a price objective of 68. A bullish response from the market helped close the gap of -10.29 to the target.

BHC

Aug 02, 2024

Target

$3.00

Current

$5.68

Performance

0.89%

On Aug 02, 2024, David Amsellem initiated coverage on BHC with a Underweight rating and target of 3. Sideways trading kept the bearish case unconfirmed with the stock at 5.68.

PCRX

Jul 03, 2024

Target

$42.00

Current

$23.75

Performance

9.65%

David Amsellem issued a Overweight recommendation for PCRX on Jul 03, 2024, price target set at 42. Investors following the Buy call captured upside momentum, with shares now at 23.75.

RVNC

May 10, 2024

Target

$11.00

Current

$3.65

Performance

9.94%

On May 10, 2024, RVNC was evaluated by David Amsellem, who gave a Overweight rating and target of 11. This case illustrates how a timely bullish rating can translate into tangible gains of 9.94%.

OGN

Apr 29, 2024

Target

$24.00

Current

$8.70

Performance

-53.97%

David Amsellem rated OGN as Overweight on Apr 29, 2024, setting a price target of 24. The stock has underperformed, dropping 53.97% despite the bullish target of 24.

Frequency Asked Questions

Who is David Amsellem?

David Amsellem is an analyst from Piper Sandler specializing in the Healthcare sector.

What is David Amsellem's success rate?

David Amsellem currently has a success rate of +64.32%.

How many ratings has David Amsellem issued?

David Amsellem has issued 36 stock ratings so far.

What is the average return of David Amsellem's calls?

Their stock ratings have generated an average return of +13.10%.

What is David Amsellem's ranking?

David Amsellem is ranked #2377 out of 4613 analysts.

What types of ratings does David Amsellem give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Amsellem?

You can follow David Amsellem by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Amsellem?

Their latest rating was a Buy on BIIB issued on 2026-04-14.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep